Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS

Nucleic Acids Research

Volumn 41, Issue 21, 2013, Pages 9634-9650

  Østergaard, Michael E ^a   Southwell, Amber L ^b   Kordasiewicz, Holly ^a   Watt, Andrew T ^a   Skotte, Niels H ^b   Doty, Crystal N ^b   Vaid, Kuljeet ^b   Villanueva, Erika B ^b   Swayze, Eric E ^a   Bennett, C Frank ^a   Hayden, Michael R ^b   Seth, Punit P ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; HUNTINGTIN; MESSENGER RNA; MUTANT PROTEIN; RIBONUCLEASE H;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; DOWN REGULATION; EMBRYO; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RAT; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE;

ALLELES; ANIMALS; BASE PAIRING; BRAIN; CELLS, CULTURED; DOWN-REGULATION; FLUORINE; HUMANS; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; RATS, SPRAGUE-DAWLEY; RIBONUCLEASE H;

EID: 84890057093     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkt725     Document Type: Article

References (49)

1. Gatchel, J.R. and Zoghbi, H.Y. (2005) Diseases of unstable repeat expansion: mechanisms and common principles. Nat. Rev. Genet., 6, 743-755.
2. Bennett, C.F. and Swayze, E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol., 50, 259-293.
3. O'Connor, T.P. and Crystal, R.G. (2006) Genetic medicines: treatment strategies for hereditary disorders. Nat. Rev. Genet., 7, 261-276.
4. MacDonald, M.E., Ambrose, C.M., Duyao, M.P., Myers, R.H., Lin, C., Srinidhi, L., Barnes, G., Taylor, S.A., James, M., Groot, N. et al. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
5. Walker, F.O. (2007) Huntington's disease. Lancet, 369, 218-228.
6. Nasir, J., Floresco, S.B., O'Kusky, J.R., Diewert, V.M., Richman, J.M., Zeisler, J., Borowski, A., Marth, J.D., Phillips, A.G. and Hayden, M.R. (1995) Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell, 81, 811-823.
7. Zhang, Y., Leavitt, B.R., van Raamsdonk, J.M., Dragatsis, I., Goldowitz, D., MacDonald, M.E., Hayden, M.R. and Friedlander, R.M. (2006) Huntingtin inhibits caspase-3 activation. EMBO J., 25, 5896-5906.
8. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B.R., Goffredo, D., Conti, L., MacDonald, M.E., Friedlander, R.M., Silani, V., Hayden, M.R. et al. (2001) Loss of huntingtin-mediated BDNF gene transcription in Huntington's Disease. Science, 293, 493-498.
9. Zeitlin, S., Liu, J.P., Chapman, D.L., Papaioannou, V.E. and Efstratiadis, A. (1995) Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet., 11, 155-163.
10. Kordasiewicz, H.B., Stanek, L.M., Wancewicz, E.V., Mazur, C., McAlonis, M.M., Pytel, K.A., Artates, J.W., Weiss, A., Cheng, S.H., Shihabuddin, L.S. et al. (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron, 74, 1031-1044.
11. DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R.K., Rajeev, K.G. et al. (2007) Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl Acad. Sci. USA, 104, 17204-17209.
12. McBride, J.L., Pitzer, M.R., Boudreau, R.L., Dufour, B., Hobbs, T., Ojeda, S.R. and Davidson, B.L. (2011) Preclinical safety of RNAimediated HTT suppression in the rhesus macaque as a potential therapy for huntington's disease. Mol. Ther., 19, 2152-2162.
13. Boudreau, R.L., Spengler, R.M. and Davidson, B.L. (2011) Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol. Ther., 19, 2169-2177.
14. Gagnon, K.T., Pendergraff, H.M., Deleavey, G.F., Swayze, E.E., Potier, P., Randolph, J., Roesch, E.B., Chattopadhyaya, J., Damha, M.J., Bennett, C.F. et al. (2010) Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry, 49, 10166-10178.
15. Hu, J., Liu, J. and Corey, D.R. (2010) Allele-selective inhibition of huntingtin expression by switching to an miRNA-like RNAi mechanism. Chem. Biol., 17, 1183-1188.
16. Hu, J., Matsui, M., Gagnon, K.T., Schwartz, J.C., Gabillet, S., Arar, K., Wu, J., Bezprozvanny, I. and Corey, D.R. (2009) Allelespecific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat. Biotechnol., 27, 478-484.
17. Yu, D., Pendergraff, H., Liu, J., Kordasiewicz, H.B., Cleveland, D.W., Swayze, E.E., Lima, W.F., Crooke, S.T., Prakash, T.P. and Corey, D.R. (2012) Single-stranded RNAs Use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell, 150, 895-908.
18. van Bilsen, P.H., Jaspers, L., Lombardi, M.S., Odekerken, J.C., Burright, E.N. and Kaemmerer, W.F. (2008) Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum. Gene. Ther., 19, 710-719.
19. Schwarz, D.S., Ding, H., Kennington, L., Moore, J.T., Schelter, J., Burchard, J., Linsley, P.S., Aronin, N., Xu, Z. and Zamore, P.D. (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet., 2, e140.
20. Lombardi, M.S., Jaspers, L., Spronkmans, C., Gellera, C., Taroni, F., Di Maria, E., Donato, S.D. and Kaemmerer, W.F. (2009) A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol., 217, 312-319.
21. Monia, B.P., Johnston, J.F., Ecker, D.J., Zounes, M.A., Lima, W.F. and Freier, S.M. (1992) Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem., 267, 19954-19962.
22. Carroll, J.B., Warby, S.C., Southwell, A.L., Doty, C.N., Greenlee, S., Skotte, N., Hung, G., Bennett, C.F., Freier, S.M. and Hayden, M.R. (2011) Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/ allele-specific silencing of mutant huntingtin. Mol. Ther., 19, 2178-2185.
23. de la Monte, S.M., Vonsattel, J.P. and Richardson, E.P. Jr (1988) Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J. Neuropathol. Exp. Neurol., 47, 516-525.
24. Pfister, E.L., Kennington, L., Straubhaar, J., Wagh, S., Liu, W., DiFiglia, M., Landwehrmeyer, B., Vonsattel, J.-P., Zamore, P.D. and Aronin, N. (2009) Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr. Biol., 19, 774-778.
25. Vickers, T.A., Koo, S., Bennett, C.F., Crooke, S.T., Dean, N.M. and Baker, B.F. (2003) Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. J. Biol. Chem., 278, 7108-7118.
26. Swayze, E.E. and Bhat, B. (2007) In: Crooke, S.T. (ed.), Antisense Drug Technology: Principles, Strategies, and Applications, 2nd edn. CRC Press, Boca Raton, pp. 143-182.
27. Miller, T.M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S.H., Andres, P.L., Mahoney, K., Allred, P., Alexander, K. et al. (2013) An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol., 12, 435-442.
28. Dolgin, E. (2012) Getting a fix on SMA. Nat. Med., 18, 1605-1605.
29. Teplova, M., Minasov, G., Tereshko, V., Inamati, G.B., Cook, P.D., Manoharan, M. and Egli, M. (1999) Crystal structure and improved antisense properties of 20-O-(2-methoxyethyl)-RNA. Nat. Struct. Biol., 6, 535-539.
30. Seth, P.P., Siwkowski, A., Allerson, C.R., Vasquez, G., Lee, S., Prakash, T.P., Wancewicz, E.V., Witchell, D. and Swayze, E.E. (2009) Short antisense oligonucleotides with novel 20-40 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem., 52, 10-13.
31. Koller, E., Vincent, T.M., Chappell, A., De, S., Manoharan, M. and Bennett, C.F. (2011) Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res., 39, 4795-4807.
32. Varani, G. and McClain, W.H. (2000) The G x U wobble base pair. A fundamental building block of RNA structure crucial to RNA function in diverse biological systems. EMBO Rep., 1, 18-23.
33. Barnes, T.W. III and Turner, D.H. (2001) Long-range cooperativity due to C5-propynylation of oligopyrimidines enhances specific recognition by uridine of ribo-adenosine over ribo-guanosine. J. Am. Chem. Soc., 123, 9186-9187.
34. Testa, S.M., Disney, M.D., Turner, D.H. and Kierzek, R. (1999) Thermodynamics of RNA-RNA duplexes with 2-or 4-thiouridines: implications for antisense design and targeting a group I intron. Biochemistry, 38, 16655-16662.
35. Egli, M., Pallan, P.S., Allerson, C.R., Prakash, T.P., Berdeja, A., Yu, J., Lee, S., Watt, A., Gaus, H., Bhat, B. et al. (2011) Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 30-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotides. J. Am. Chem. Soc., 133, 16642-16649.
36. Wu, H., Lima, W.F., Zhang, H., Fan, A., Sun, H. and Crooke, S.T. (2004) Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem., 279, 17181-17189.
37. Lima, W.F., Nichols, J.G., Wu, H., Prakash, T.P., Migawa, M.T., Wyrzykiewicz, T.K., Bhat, B. and Crooke, S.T. (2004) Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J. Biol. Chem., 279, 36317-36326.
38. Nowotny, M., Gaidamakov, S.A., Ghirlando, R., Cerritelli, S.M., Crouch, R.J. and Yang, W. (2007) Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription. Mol. Cell, 28, 264-276.
39. Wu, H., Lima, W.F. and Crooke, S.T. (1999) Properties of cloned and expressed human RNase H1. J. Biol. Chem., 274, 28270-28278.
40. Lima, W.F., Rose, J.B., Nichols, J.G., Wu, H., Migawa, M.T., Wyrzykiewicz, T.K., Siwkowski, A.M. and Crooke, S.T. (2007) Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate. Mol. Pharmacol., 71, 83-91.
41. Saha, A.K., Caulfield, T.J., Hobbs, C., Upson, D.A., Waychunas, C. and Yawman, A.M. (1995) 5'-Me-DNA-a new oligonucleotide analog: synthesis and biochemical properties. J. Org. Chem., 60, 788-789.
42. Li, F., Sarkhel, S., Wilds, C.J., Wawrzak, Z., Prakash, T.P., Manoharan, M. and Egli, M. (2006) 20-fluoroarabino-and arabinonucleic acid show different conformations, resulting in deviating RNA affinities and processing of their heteroduplexes with RNA by RNase H. Biochemistry, 45, 4141-4152.
43. Williams, D.M., Benseler, F. and Eckstein, F. (1991) Properties of 2'-fluorothymidine-containing oligonucleotides: interaction with restriction endonuclease EcoRV. Biochemistry, 30, 4001-4009.
44. Pallan, P.S., Allerson, C.R., Berdeja, A., Seth, P.P., Swayze, E.E., Prakash, T.P. and Egli, M. (2012) Structure and nuclease resistance of 20, 40-constrained 20-O-methoxyethyl (cMOE) and 20-O-ethyl (cEt) modified DNAs. Chem. Commun., 48, 8195-8197.
45. Southwell, A.L., Warby, S.C., Carroll, J.B., Doty, C.N., Skotte, N.H., Zhang, W., Villanueva, E.B., Kovalik, V., Xie, Y., Pouladi, M.A. et al. (2013) A fully humanized transgenic mouse model of Huntington disease. Hum. Mol. Genet., 22, 18-34.
46. Zuccato, C., Valenza, M. and Cattaneo, E. (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev., 90, 905-981.
47. Evers, M.M., Pepers, B.A., van Deutekom, J.C.T., Mulders, S.A.M., den Dunnen, J.T., Aartsma-Rus, A., van Ommen, G.-J.B. and van Roon-Mom, W.M.C. (2011) Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS One, 6, e24308.
48. Sathasivam, K., Neueder, A., Gipson, T.A., Landles, C., Benjamin, A.C., Bondulich, M.K., Smith, D.L., Faull, R.L.M., Roos, R.A.C., Howland, D. et al. (2013) Aberrant splicing of HTT generates the pathogenic Exon 1 protein in Huntington disease. Proc. Natl Acad. Sci. USA, 110, 2366-2370.
49. Lombardi, M.S., Jaspers, L., Spronkmans, C., Gellera, C., Taroni, F., Di Maria, E., Donato, S.D. and Kaemmerer, W.F. (2009) A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol., 217, 312-319.